These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 31131678

  • 1. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
    Eaton JE, Nelson KM, Gossard AA, Carey EJ, Tabibian JH, Lindor KD, LaRusso NF.
    Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
    [Abstract] [Full Text] [Related]

  • 2. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
    Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, Lu X, Xu J, Chuang JC, Billin AN, Li G, Chung C, Subramanian GM, Myers RP, Bowlus CL, Kowdley KV.
    Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
    [Abstract] [Full Text] [Related]

  • 3. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
    Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M, European PSC norUDCA Study Group.
    J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study.
    Eksteen B, Bowlus CL, Montano-Loza AJ, Lefebvre E, Fischer L, Vig P, Martins EB, Ahmad J, Yimam KK, Pockros PJ, Feld JJ, Minuk G, Levy C.
    Hepatol Commun; 2021 Mar; 5(3):478-490. PubMed ID: 33681680
    [Abstract] [Full Text] [Related]

  • 5. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F.
    Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
    [Abstract] [Full Text] [Related]

  • 6. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
    Trauner M, Bowlus CL, Gulamhusein A, Hameed B, Caldwell SH, Shiffman ML, Landis C, Muir AJ, Billin A, Xu J, Liu X, Lu X, Chung C, Myers RP, Kowdley KV.
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287
    [Abstract] [Full Text] [Related]

  • 7. Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF.
    Fossdal G, Mjelle AB, Wiencke K, Bjørk I, Gilja OH, Folseraas T, Karlsen TH, Rosenberg W, Giil LM, Vesterhus M.
    JHEP Rep; 2021 Oct; 3(5):100328. PubMed ID: 34485881
    [Abstract] [Full Text] [Related]

  • 8. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
    Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL.
    J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
    [Abstract] [Full Text] [Related]

  • 9. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.
    Tabibian JH, Gossard A, El-Youssef M, Eaton JE, Petz J, Jorgensen R, Enders FB, Tabibian A, Lindor KD.
    Am J Ther; 2017 Feb; 24(1):e56-e63. PubMed ID: 24914504
    [Abstract] [Full Text] [Related]

  • 10. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis.
    Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD.
    Am J Gastroenterol; 2005 Feb; 100(2):308-12. PubMed ID: 15667487
    [Abstract] [Full Text] [Related]

  • 11. An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort.
    Bakhshi Z, Hilscher MB, Gores GJ, Harmsen WS, Viehman JK, LaRusso NF, Gossard AA, Lazaridis KN, Lindor KD, Eaton JE.
    J Gastroenterol; 2020 May; 55(5):523-532. PubMed ID: 31932891
    [Abstract] [Full Text] [Related]

  • 12. Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning.
    Eaton JE, Vesterhus M, McCauley BM, Atkinson EJ, Schlicht EM, Juran BD, Gossard AA, LaRusso NF, Gores GJ, Karlsen TH, Lazaridis KN.
    Hepatology; 2020 Jan; 71(1):214-224. PubMed ID: 29742811
    [Abstract] [Full Text] [Related]

  • 13. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
    Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, Mayo MJ, Muir AJ, Trotter JF, Leeming DJ, Karsdal MA, Jaros MJ, Ling L, Kim KH, Rossi SJ, Somaratne RM, DePaoli AM, Beuers U.
    J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis.
    Liu X, Wang H, Liu X, Bridle K, Crawford D, Liang X.
    Pharmacol Ther; 2022 Sep; 237():108163. PubMed ID: 35271884
    [Abstract] [Full Text] [Related]

  • 15. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis.
    Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD.
    Am J Gastroenterol; 2000 Sep; 95(9):2338-42. PubMed ID: 11007239
    [Abstract] [Full Text] [Related]

  • 16. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.
    Al Mamari S, Djordjevic J, Halliday JS, Chapman RW.
    J Hepatol; 2013 Feb; 58(2):329-34. PubMed ID: 23085647
    [Abstract] [Full Text] [Related]

  • 17. Short-term prognostic factors for primary sclerosing cholangitis.
    Watanabe T, Hirano K, Tada M, Isayama H, Mizuno S, Arizumi T, Toda N, Sugawara Y, Kokudo N, Koike K.
    J Hepatobiliary Pancreat Sci; 2015 Jun; 22(6):486-90. PubMed ID: 25826613
    [Abstract] [Full Text] [Related]

  • 18. A pilot study of etanercept in the treatment of primary sclerosing cholangitis.
    Epstein MP, Kaplan MM.
    Dig Dis Sci; 2004 Jan; 49(1):1-4. PubMed ID: 14992426
    [Abstract] [Full Text] [Related]

  • 19. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial.
    Van Thiel DH, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, Irish W, McMichael J, Starzl TE.
    Am J Gastroenterol; 1995 Mar; 90(3):455-9. PubMed ID: 7532912
    [Abstract] [Full Text] [Related]

  • 20. Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial.
    Hatami B, Mosala M, Hassani AH, Ardakani MJE, Gholami S, Zali MR.
    Pharmacol Res Perspect; 2022 Aug; 10(4):e00984. PubMed ID: 35822553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.